{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:52:20Z","timestamp":1793407940915,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-025-04161-0","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T21:18:52Z","timestamp":1755724732000},"page":"1604-1613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Dosimetry Models and Dose Thresholds for Predicting Pathologic Response to Yttrium-90 Radioembolization with Glass Microspheres"],"prefix":"10.1007","volume":"48","author":[{"given":"Kurt T.","family":"Pianka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Barahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeet","family":"Minocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas W.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Schnickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Krishnasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-9772","authenticated-orcid":false,"given":"Zachary T.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"4161_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1478-3231.2011.02473.x","volume":"31","author":"M Fujiki","year":"2011","unstructured":"Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Necessity or option? Liver Int. 2011;31:1081\u20139. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02473.x.","journal-title":"Liver Int"},{"key":"4161_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"key":"4161_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","volume":"271","author":"J DiNorcia","year":"2020","unstructured":"DiNorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, et al. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US multicenter HCC transplant consortium. Ann Surg. 2020;271:616. https:\/\/doi.org\/10.1097\/SLA.0000000000003253.","journal-title":"Ann Surg"},{"key":"4161_CR4","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1097\/01.TP.0000145892.97114.EE","volume":"78","author":"M Ravaioli","year":"2004","unstructured":"Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation. 2004;78:1780. https:\/\/doi.org\/10.1097\/01.TP.0000145892.97114.EE.","journal-title":"Transplantation"},{"key":"4161_CR5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.31318","volume":"73","author":"A Gabr","year":"2021","unstructured":"Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, et al. Liver transplantation following Yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology. 2021;73:998. https:\/\/doi.org\/10.1002\/hep.31318.","journal-title":"Hepatology"},{"key":"4161_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.jvir.2018.06.027","volume":"29","author":"A Gabr","year":"2018","unstructured":"Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:1502\u201310. https:\/\/doi.org\/10.1016\/j.jvir.2018.06.027.","journal-title":"J Vasc Interv Radiol"},{"key":"4161_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"key":"4161_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","volume":"79","author":"A Riaz","year":"2011","unstructured":"Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.062.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4161_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48:580\u20133. https:\/\/doi.org\/10.1007\/s00259-020-04976-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4161_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192\u2013201. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatology"},{"key":"4161_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jvir.2020.12.019","volume":"32","author":"B Toskich","year":"2021","unstructured":"Toskich B, Vidal LL, Olson MT, Lewis JT, LeGout JD, Sella DM, et al. Pathologic response of hepatocellular carcinoma treated with Yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: a validation study. J Vasc Interv Radiol. 2021;32:518-526.e1. https:\/\/doi.org\/10.1016\/j.jvir.2020.12.019.","journal-title":"J Vasc Interv Radiol"},{"key":"4161_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatology. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatology"},{"key":"4161_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06813-8","author":"KT Pianka","year":"2024","unstructured":"Pianka KT, Barahman M, Minocha J, Redmond JW, Schnickel GT, Rose SC, et al. Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06813-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4161_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e1brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"4161_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464\u201370. https:\/\/doi.org\/10.1053\/jhep.2001.22172.","journal-title":"Hepatology"},{"key":"4161_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1053\/j.gastro.2006.02.010","volume":"130","author":"SW Biggins","year":"2006","unstructured":"Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652\u201360. https:\/\/doi.org\/10.1053\/j.gastro.2006.02.010.","journal-title":"Gastroenterology"},{"key":"4161_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.57.9151.","journal-title":"J Clin Oncol"},{"key":"4161_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jvir.2010.10.029","volume":"22","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265\u201378. https:\/\/doi.org\/10.1016\/j.jvir.2010.10.029.","journal-title":"J Vasc Interv Radiol"},{"key":"4161_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816\u201330. https:\/\/doi.org\/10.1148\/radiol.2018181494.","journal-title":"Radiology"},{"key":"4161_CR20","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jvir.2017.06.019","volume":"28","author":"O Khalilzadeh","year":"2017","unstructured":"Khalilzadeh O, Baerlocher MO, Shyn PB, Connolly BL, Devane AM, Morris CS, et al. Proposal of a new adverse event classification by the society of interventional radiology standards of practice committee. J Vasc Interv Radiol. 2017;28:1432\u20137. https:\/\/doi.org\/10.1016\/j.jvir.2017.06.019.","journal-title":"J Vasc Interv Radiol"},{"key":"4161_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvir.2022.10.011","volume":"34","author":"MO Baerlocher","year":"2023","unstructured":"Baerlocher MO, Nikolic B, Sze DY. Adverse event classification: clarification and validation of the society of interventional radiology specialty-specific system. J Vasc Interv Radiol. 2023;34:1\u20133. https:\/\/doi.org\/10.1016\/j.jvir.2022.10.011.","journal-title":"J Vasc Interv Radiol"},{"key":"4161_CR22","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1007\/s00259-022-05776-y","volume":"49","author":"SA Montazeri","year":"2022","unstructured":"Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022;49:3892\u20137. https:\/\/doi.org\/10.1007\/s00259-022-05776-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4161_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7:843\u201350. https:\/\/doi.org\/10.1016\/S2468-1253(22)00091-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4161_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65:264\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266211.","journal-title":"J Nucl Med"},{"key":"4161_CR25","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49:3340\u201352. https:\/\/doi.org\/10.1007\/s00259-022-05774-0.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04161-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:09:29Z","timestamp":1761786569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04161-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04161-0","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KF reports fees from Bayer, Guerbet, and Ascelia Pharma. ZB reports fees from Boston Scientific. For all other authors, conflicts of interest: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study has obtained IRB approval from the UCSD Institutional Review Board and the need for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"For this type of study consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}